New approaches and treatments are needed, especially for high histological grade, advanced tumor stage, TP53 mutated form (which is associated with HuR overexpression in breast cancer [31]), and in the case of microsatellite instability/mismatch repair (MMR) deficiency, which are associated with a poor prognosis [32,33,34]. This evidence concerns the gene ELAVL1 and breast cancer.